Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim
This article was originally published in Scrip
Executive Summary
Merck & Co. failed to convince the FDA to permit the firm to market its cholesterol-lowering medications Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as therapies to reduce the risk of cardiovascular (CV) events – CV death, nonfatal heart attacks and strokes, hospitalization for unstable angina or the need for revascularization – in patients with coronary heart disease.
You may also be interested in...
New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value
Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.
Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.